Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. - Wikidata - wikimedia - TriplyDB

Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.

Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.

http://www.wikidata.org/entity/Q37193600

about

Liraglutide reduces body weight by upregulation of adenylate cyclase 3.Incretin-based therapies in prediabetes: Current evidence and future perspectives Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.Pharmacotherapy for obesity: novel agents and paradigms.GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.Liraglutide: an injectable option for the management of obesity.Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice.Dissecting the relationship between obesity and hyperinsulinemia: Role of insulin secretion and insulin clearance.Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.European Guidelines for Obesity Management in Adults.Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.Effects of Obex in Overweight and Obese Subjects With or Without Impaired Fasting Glucose: A Pilot Study.Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): A randomised, double-blind, controlled trial.Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol.

P2860

Q33920059-157EB17D-30BF-4A01-AF1A-C8F3A0786782 Q34699191-5F16C4B4-C10A-4994-9635-DCC9BEE73829 Q35209811-A04A0F10-C349-4A10-ACB3-5A8DCA7A6CF8 Q37353814-51D2B0A2-6FE3-45C9-85C1-A6C437FFB0E5 Q37470522-E776C690-5F58-4260-BA67-EDFC8E9472FB Q37712227-C7D6585F-B345-4CF8-89EB-721F9B86FDA3 Q38266329-2898C568-50FF-47FF-B305-3AFD6EB932CB Q38488897-60FE414E-A967-4579-925D-8ECE398D0895 Q38702260-233D5794-83A2-4E1F-BF29-2A277CA69C3E Q38794395-378CBB90-85D0-433A-AF76-112731E772C9 Q39489506-34122BD7-4718-4C8A-854C-E61D9A49E9E1 Q42060078-6E3130C1-BE94-4836-BD08-497D00A2DD01 Q46325597-E820F064-3210-499A-BEC7-0FA69F55109F Q47094048-A8D98589-AB87-419E-8FC8-06E136C76E8E Q48935307-9A610190-BA89-4684-BA19-7DD96D543658 Q51269837-8F9B2995-55B3-4082-BB49-DCF4A8A6D43A Q55137041-62994D87-E53A-46D2-8160-FFF06F7C3DB2 Q55215230-5931BD14-B0F3-4D54-ACC3-461F999E4240

P2860

Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.

http://www.wikidata.org/entity/Q37193600

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Benefits of liraglutide treatm ...... individuals with prediabetes.

@en

Benefits of liraglutide treatm ...... individuals with prediabetes.

@nl

type

label

Benefits of liraglutide treatm ...... individuals with prediabetes.

@en

Benefits of liraglutide treatm ...... individuals with prediabetes.

@nl

prefLabel

Benefits of liraglutide treatm ...... individuals with prediabetes.

@en

Benefits of liraglutide treatm ...... individuals with prediabetes.

@nl

P1433

Q37193600-3EC85993-D0D8-438F-9CF3-4E33D429A21D

P1476

Q37193600-E7531AE6-1EEB-4E2E-A99B-0A3F18BA14DF

P2093

Q37193600-06E20F0B-05C5-4585-90FC-460DB969A7A7

Q37193600-1BF3D7D8-5313-49C5-9698-5256409034FE

Q37193600-39F91500-54FD-4FE3-B93A-2CE7D5437FC3

Q37193600-46E53075-C4BD-4DB8-8F66-25A7099496A9

Q37193600-5218973C-7A5F-4D0C-B856-7E8E7D5A6249

Q37193600-71C59C52-92B3-4FDC-892F-E3646CD259CE

Q37193600-AF6284D7-B8F9-4801-BE37-109A229CDFDB

Q37193600-CC0F86A1-B184-4A73-8F20-04EA54AED430

Q37193600-D5D08759-61B5-410A-81C6-CC6C0ECDC44F

Q37193600-E9D9DDB7-A445-4DB9-807E-C24DF5E35606

P2860

Q37193600-05729736-651F-45B3-A845-192CF5A83286

Q37193600-198F4AF6-4736-4BF5-AAB3-48208359E142

Q37193600-1ADF0CB0-CE9E-4083-9AB1-F91E95F22224

Q37193600-25535457-220D-465B-8D9F-AB1327E5BC09

Q37193600-26838DAE-E54E-4D5F-9835-354185E9D5CD

Q37193600-27684FCA-EE3E-476E-949A-855BCC7E0578

Q37193600-29EF3B12-003C-4195-8429-33066D9C2476

Q37193600-2A85B5DE-8C74-4860-8801-7C0A284DA6B1

Q37193600-2CDAEBE6-6F5E-44A4-A7D5-711E4F169C39

Q37193600-323B1E16-0E48-4F66-8552-E0B602801095

P304

Q37193600-61ABCD74-5236-4B55-A8F5-167A76B061F0

P31

Q37193600-1CD21697-BCC1-45B6-B3D4-22C8BA4DE908

P356

Q37193600-BF3D51DF-C568-4F9C-8A79-CEEC12B34218

P407

Q37193600-091F0EA2-7D07-468E-AE19-27686F602214

P433

Q37193600-228A37FB-1452-430C-9043-2638A7C06415

P478

Q37193600-183965B4-84E6-48D8-994E-3A46EDD4269F

P50

Q37193600-7DD05151-B7BD-41C4-AB2C-82DF332E9C19

Q37193600-D7D5B6CC-448D-4909-A735-723E06D77BC9

P577

Q37193600-1E8A0369-F080-4B58-AD1F-3B53081CE9A2

P5875

Q37193600-2A9C2A54-AAFB-4887-846D-24FF7AA384DF

P698

Q37193600-4014F46C-C346-455F-B3B0-D6D57C4201F1

P921

Q37193600-FAE0A867-DFD5-46C9-AAF3-70E8DAEFD939

P932

Q37193600-C1FB2977-B065-4CCA-A5C9-0C00DEAB24F5

P356

P1433

P1476

Benefits of liraglutide treatm ...... individuals with prediabetes.

@en

P2093

Alice Liu

http://www.w3.org/2001/XMLSchema#string

Danit Ariel

http://www.w3.org/2001/XMLSchema#string

Fahim Abbasi

http://www.w3.org/2001/XMLSchema#string

Hector Ochoa

http://www.w3.org/2001/XMLSchema#string

Kaylene Grove

http://www.w3.org/2001/XMLSchema#string

Patricia Schaaf

http://www.w3.org/2001/XMLSchema#string

Sun H Kim

http://www.w3.org/2001/XMLSchema#string

Vanessa Tomasso

http://www.w3.org/2001/XMLSchema#string

Yeheng V Liu

http://www.w3.org/2001/XMLSchema#string

Yii-Der Ida Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

Standards of medical care in diabetes--2013

Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.

GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons.

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

P304

3276-3282

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-0354

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Cindy Lamendola

P577

2013-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

247771511

http://www.w3.org/2001/XMLSchema#string

P698

23835684

http://www.w3.org/2001/XMLSchema#string

P921

P932

3781545

http://www.w3.org/2001/XMLSchema#string